We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pulmonary Eosinophilia Indicates Onset of Allergic Bronchopulmonary Aspergillosis

By LabMedica International staff writers
Posted on 13 Dec 2021
Print article
Image: Histopathology of Allergic bronchopulmonary aspergillosis. Grocott\'s Methenamine Silver Stain  shows branching and helps to confirm that the black structures are indeed fungal hyphae (Photo courtesy of Doctorlib)
Image: Histopathology of Allergic bronchopulmonary aspergillosis. Grocott\'s Methenamine Silver Stain shows branching and helps to confirm that the black structures are indeed fungal hyphae (Photo courtesy of Doctorlib)
Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder caused by type 2 immune responses to Aspergillus. This pathology usually develops after the onset of bronchial asthma (BA) or cystic fibrosis. Rates differ among countries, but appear to be increasing around the world with the increase of BA.

Several diagnostic criteria for ABPA have been proposed, such as a history of BA or cystic fibrosis, characteristic radiographic pulmonary opacities including central dilatation of the bronchus, elevated immunoglobulin (Ig)E levels, and hypersensitivity reaction to Aspergillus including elevated IgE antibodies against Aspergillus fumigatus and/or IgG antibodies for Aspergillus. ABPA and chronic eosinophilic pneumonia (CEP) both display peripheral eosinophilia as well as pulmonary infiltration, together described as pulmonary eosinophilia, and differentiation is sometimes problematic.

Pulmonologists at the Osaka Toneyama Medical Center (Osaka, Japan) performed a retrospective, single-center study that included patients that fulfilled the diagnostic criteria for ABPA, which included a history of BA or cystic fibrosis and both of the following: positive immediate cutaneous hypersensitivity to Aspergillus antigen or specific IgE to A. fumigatus, and elevated total IgE level in serum  > 1000 IU/mL. Also the presence of precipitating or IgG antibodies against A. fumigatus in serum; pulmonary opacities consistent with ABPA on radiographic imaging; and total eosinophil count  > 500 cells/µL in steroid-naïve patients were considered.

Patients were assigned to either the eosinophilic pneumonia (EP) group or Non-EP group, defined according to findings on high-resolution computed tomography (HRCT). The EP group included patients with HRCT findings compatible with CEP; i.e., the presence of peripheral consolidation (p-consolidation) or ground-glass opacities (GGO), with no evidence of high-attenuation mucus. The Non-EP group comprised the remaining patients, who showed classical findings of ABPA such as mucoid impaction. Differences between the groups were analyzed.

The investigators reported that baseline characteristics, frequency of a history of CEP (EP, 50% versus Non-EP, 26%) and tentative diagnosis of CEP before diagnosis of ABPA (67% versus 16%) did not differ significantly between groups. Although elevated absolute eosinophil count and Aspergillus-specific immunoglobulin E titers did not differ significantly between groups, the Non-EP group showed a strong positive correlation between these values (R  = 0.7878). All patients showed peripheral eosinophilia (median, 1,540 cells/μL), elevated level of IgE (median, 2,802 IU/mL) and positive reactions for Aspergillus-specific IgE (median, 20.7 IU/mL).

The Non-EP group displayed significantly higher levels of the fungal marker beta-D glucan (median, 11.7 pg/mL; interquartile range, 6.7–18.4 pg/mL) than the EP group (median, 6.6 pg/mL; interquartile range, 5.2–9.3 pg/ml). Both groups exhibited frequent recurrence of shadows on X-rays but no cases in the EP group had progressed to the Non-EP group at the time of relapse.

The authors concluded that the ABPA subgroup with imaging findings resembling CEP experienced frequent recurrences, as in typical ABPA. In pulmonary eosinophilia, even if there are no shadows indicating apparent mucous change, the Aspergillus-specific immunoglobulin E level is important in obtaining an accurate diagnosis and in the selection of appropriate therapies for this type of ABPA. The study was published on November 18, 2021 in the journal Allergy, Asthma & Clinical Immunology.

Related Links:
Osaka Toneyama Medical Center

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Vaginitis Test
Allplex Vaginitis Screening Assay
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.